Home » Stocks » ADMA

ADMA Biologics Inc. (ADMA)

Stock Price: $2.31 USD -0.04 (-1.70%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $2.34 +0.03 (1.30%) Feb 26, 7:58 PM
Market Cap 218.41M
Revenue (ttm) 40.30M
Net Income (ttm) -66.90M
Shares Out 87.70M
EPS (ttm) -0.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $2.31
Previous Close $2.35
Change ($) -0.04
Change (%) -1.70%
Day's Open 2.37
Day's Range 2.26 - 2.41
Day's Volume 2,299,387
52-Week Range 1.45 - 4.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 week ago

Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.

Other stocks mentioned: AVIR, BNTX, LXRX, MRNA
Zacks Investment Research - 1 week ago

Adma Biologics (ADMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 1 month ago

Achieved Fourth Quarter 2020 Preliminary Unaudited Total Revenues of $13.9 Million, the Highest Revenue Quarter for the Company Since Inception

Seeking Alpha - 1 month ago

ADMA Biologics: A Perfect Storm

GlobeNewsWire - 1 month ago

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketi...

GlobeNewsWire - 2 months ago

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 16, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketi...

Zacks Investment Research - 2 months ago

ADMA Biologics (ADMA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Seeking Alpha - 3 months ago

ADMA Biologics recently reported its Q3 earnings with a beat on EPS and revenue. In addition, the company reported encouraging commercial progress for its IVIG products despite the COVID-19 he...

GlobeNewsWire - 3 months ago

RAMSEY, N.J. and BOCA RATON, Fla., Nov. 10, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated...

Seeking Alpha - 3 months ago

ADMA Biologics' (ADMA) CEO Adam Grossman on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Adma Biologics (ADMA) delivered earnings and revenue surprises of 9.52% and 7.64%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

Generated Total Revenues of $ 28. 3 Million for the First Nine Months of 2020 , Reflecting a 63 % Increase Over the Same Prior Year Period

GlobeNewsWire - 3 months ago

Conference Call Scheduled for Thursday, November 5, 2020, at 4:30 p.m. ET Conference Call Scheduled for Thursday, November 5, 2020, at 4:30 p.m. ET

Zacks Investment Research - 3 months ago

On ADMA Biologics' (ADMA) third-quarter earnings call, investor focus will be on the sales performance of its newly approved immunoglobulin products, Asceniv and Bivigam.

Zacks Investment Research - 3 months ago

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated...

Zacks Investment Research - 4 months ago

Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.

Zacks Investment Research - 4 months ago

ADMA Biologics (ADMA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

GlobeNewsWire - 5 months ago

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 09, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedica...

GlobeNewsWire - 5 months ago

ImmunoRank Offers a Faster, Simpler, More Cost Effective Way to Identify High Titer Convalescent Plasma for Use in Both Treating COVID-19 Patients and for Creating COVID-19 Hyperimmune Globulins

GlobeNewsWire - 5 months ago

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 02, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedica...

InvestorPlace - 5 months ago

The pandemic highlights how far medical science has come. It also highlights how exciting the future is.

Other stocks mentioned: AZN, BNTX, CERS, LMNL, PFE, SONN
Zacks Investment Research - 6 months ago

Investors need to pay close attention to ADMA stock based on the movements in the options market lately.

The Motley Fool - 6 months ago

Shares of ADMA Biologics are on the move following the FDA's authorization of convalescent plasma for the treatment of COVID-19 patients.

The Motley Fool - 6 months ago

Convalescent plasma holds promise for treating COVID-19, but it's still unproven.

Other stocks mentioned: EBS, KMDA
Benzinga - 6 months ago

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts be...

Benzinga - 6 months ago

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use ...

Other stocks mentioned: CERS, GRFS, KMDA, LMNL, SONN, THMO, TTOO
The Motley Fool - 6 months ago

The FDA's emergency use authorization of convalescent plasma therapy is sending these three stocks higher today.

Other stocks mentioned: IBIO
Seeking Alpha - 6 months ago

ADMA Biologics has shown substantial progress of late, opening another plasma collection facility and growing sales 78% in H1 2020 over the prior year.

24/7 Wall Street - 6 months ago

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: APHA, ESTE, FLMN, QUIK
Seeking Alpha - 6 months ago

ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Adma Biologics (ADMA) delivered earnings and revenue surprises of -21.05% and -24.28%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

Generated Total Revenues of $18.0 Million for the First Half of 2020, Reflecting a 78% Increase Over First Half of 2019

GlobeNewsWire - 6 months ago

Conference Call Scheduled for Wednesday, August 5, 2020, at 4:30 p.m. ET Conference Call Scheduled for Wednesday, August 5, 2020, at 4:30 p.m. ET

Zacks Investment Research - 7 months ago

Investors need to pay close attention to ADMA stock based on the movements in the options market lately.

GlobeNewsWire - 7 months ago

RAMSEY, N.J. and BOCA RATON, Fla. and KNOXVILLE, Tenn., July 06, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company ded...

Seeking Alpha - 7 months ago

ADMA Biologics: Benefit From Production Ramp

GlobeNewsWire - 8 months ago

RAMSEY, N.J. and BOCA RATON, Fla., June 23, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturi...

Zacks Investment Research - 8 months ago

Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.

GlobeNewsWire - 9 months ago

RAMSEY, N.J. and BOCA RATON, Fla., May 07, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturin...

Seeking Alpha - 9 months ago

ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Adma Biologics (ADMA) delivered earnings and revenue surprises of -100.00% and -4.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 10 months ago

ADMA Biologics: A Compelling Value At Current Price Levels

Seeking Alpha - 11 months ago

ADMA Biologics: Not Immune To Coronavirus Sell-Off Despite Their Ability To Help

Seeking Alpha - 11 months ago

ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 11 months ago

Company Offers Assistance with Coronavirus Global Health Initiatives

GlobeNewsWire - 1 year ago

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturi...

GlobeNewsWire - 1 year ago

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 11, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marke...

The Motley Fool - 1 year ago

The company's secondary stock offering was priced below its prior-day closing price.

GlobeNewsWire - 1 year ago

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 06, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) an end-to-end commercial biopharmaceutical company dedicate...

About ADMA

ADMA Biologics, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposur... [Read more...]

Industry
Biotechnology
Founded
2004
CEO
Adam S. Grossman
Employees
313
Stock Exchange
NASDAQ
Ticker Symbol
ADMA
Full Company Profile

Financial Performance

In 2019, ADMA Biologics's revenue was $29.35 million, an increase of 72.79% compared to the previous year's $16.99 million. Losses were -$48.28 million, -26.56% less than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for ADMA Biologics stock is "Buy." The 12-month stock price forecast is 8.83, which is an increase of 282.25% from the latest price.

Price Target
$8.83
(282.25% upside)
Analyst Consensus: Buy